ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome

Erin M. Parry(Broad Institute), Catherine J. Wu(Dana-Farber Cancer Institute), Giacomo Oliveira(Dana-Farber Cancer Institute), Julien Broséus(Inserm), Beenu Thakral(Post Graduate Institute of Medical Education and Research), Nitin Jain(Parul University), Romain Guièze(Broad Institute), Annabelle Anandappa(Harvard University), Connor Johnson(Broad Institute), Noelia Purroy(Universitat Autònoma de Barcelona), Lillian Werner(Dana-Farber Cancer Institute), Peter V. Kharchenko(Fleet Science Center), Constantine S. Tam(The Alfred Hospital), Nathan Dangle(Memorial Sloan Kettering Cancer Center), Stephanie Deng(Dana-Farber Cancer Institute), Camilla K. Lemvigh(Technical University of Denmark), Kenneth J. Livak(Broad Institute), Pavan Bachireddy(Broad Institute), Binyamin A. Knisbacher(Broad Institute), Pierre Feugier(Inserm), Shanye Yin(Albert Einstein College of Medicine), Lars Rønn Olsen(Copenhagen University Hospital), Shuqiang Li(Anhui Normal University), Sébastien Hergalant(Inserm), Sachet A. Shukla(The University of Texas MD Anderson Cancer Center), Teddy Huang(Dana-Farber Cancer Institute), Joseph D. Khoury(University of Nebraska Medical Center), Jaclyn M. Long(Broad Institute), William G. Wierda(University of Maryland, Baltimore), Neil Ruthen(Dana-Farber Cancer Institute), Wandi Zhang(Dana-Farber Cancer Institute), Michael Dickinson(The University of Melbourne), Gad Getz(Broad Institute), Satyen H. Gohil(Broad Institute), Donna Neuberg(Otsuka (Japan))
Cancer Cell
September 21, 2023
Cited by 73


Related Papers